Trial Profile

A Phase 3, Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of Recombinant Human Thyrotropin (rhTSH) for Radioactive Iodine (RAI) Remnant Ablation in Postoperative Participants With Differentiated Thyroid Cancer (DTC)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Recombinant human thyroid stimulating hormone-Suzhou Zelgen Biopharmaceuticals (Primary) ; Iodine radioactive
Indications Carcinoma; Thyroid cancer
Focus Registrational; Therapeutic Use
Sponsors Suzhou Zelgen Biopharmaceuticals

08 Sep 2026 Status changed from recruiting to completed.
20 Oct 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
20 Oct 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com